Drug Profile
MDR 104
Alternative Names: MDR 10X; MDR-104Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Medeor Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal transplant rejection
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Renal-transplant-rejection in USA (Parenteral, Infusion)
- 10 May 2017 Preclinical trials in Renal transplant rejection in USA (Parenteral) (Medeor Therapeutics' website, May 2017)
- 28 Apr 2017 Medeor Therapeutics has patent protection for technology underlying the manufacturing process of its therapies